Icosavax keeps up the excitement for its VLP 'soccer balls,' earning the RA Capital stamp of approval in $100M Series B
Roughly a year and a half since its last raise, Icosavax scored a fresh goal Wednesday morning in nabbing new funds for its soccer ball-like VLP vaccine tech. And the Seattle-based company is bringing in a high-profile set of new investors.
Icosavax unveiled a $100 million Series B, backed by Peter Kolchinsky’s RA Capital Management and Perceptive Advisors, among others. Kolchinsky scores a board seat with the raise, as the biotech plans to use its newfound cash to advance a handful of vaccine programs for SARS-CoV-2 and viruses that trigger pneumonia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.